Effectiveness of antiplatelet therapy in atherosclerotic disease: Comparing the ASA low-response prevalence in CVD, CAD and PAD

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 2, 2014, Pages 190-201

  Meves, Saskia H ^a   Hummel, Thomas ^a   Endres, Heinz G ^b   Mayböck, Nora ^a   Kaiser, Andreas F C ^a   Schröder, Kay D ^a   Rüdiger, Katja ^a   Overbeck, Ursula ^a   Mumme, Achim ^a   Mügge, Andreas ^a   Neubauer, Horst ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Aspirin; Coronary artery disease; Impedance aggregometry; Peripheral artery disease; Platelet aggregation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; CLOPIDOGREL; HEMOGLOBIN A1C;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; ATHEROSCLEROSIS; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; LEUKOCYTE COUNT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; TREATMENT RESPONSE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASPIRIN; CORONARY ARTERY DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION INHIBITORS; PREVALENCE; STROKE;

EID: 84894660699     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0919-7     Document Type: Article

References (55)

1. Viles-Gonzalez JF, Fuster V, Badimon JJ (2004) Atherothrombosis: a widespread disease with unpredictable and life-threatening consequences. Eur Heart J 25:1197-1207
2. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE, Redgrave JN, Bull LM, Welch SJ, Cuthbertson FC, Binney LE, Gutnikov SA, Anslow P, Banning AP, Mant D, Mehta Z, Oxford Vascular Study (2005) Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366:1773-1783
3. Alberts MJ, Bhatt DL, Mas JL, Ohman EM, Hirsch AT, Röther J, Salette G, Goto S, Smith SC Jr, Liau CS, Wilson PW, Steg PG, Reduction of Atherothrombosis for Continued Health Registry Investigators (2009) Three-year follow-up and event rates in the international reduction of atherothrombosis for continued health registry. Eur Heart J 30:2318-2326
4. Yakubov S (2009) Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome. Curr Med Res Opin 25:2631-2641
5. Zeymer U, Senges J, Parhofer KG, Röther J (2008) Risk factors and event rates in patients with atherothrombotic disease in Germany: results of the reach registry. Dtsch Arztebl Int 105:769-775
6. Suárez C, Zeymer U, Limbourg T, Baumgartner I, Cacoub P, Poldermans D, Röther J, Bhatt DL, Steg PG, Reach Registry Investigators (2010) Influence of polyvascular disease on cardiovascular event rates: insights from the reach registry. Vasc Med 15:259-265
7. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T, Patrono C, Roncaglioni MC, Zanchetti A (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373:1849-1860
8. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336:195-198
9. Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF (2010) Clopidogrel non-responsiveness and risk of cardiovascular morbidity: an updated meta-analysis. Thromb Haemost 103:841-848
10. Weber AA, Adamzik M, Bachmann HS, Görlinger K, Grandoch M, Leineweber K, Müller-Beissenhirtz H, Wenzel F, Naber C, Interdisciplinary Study Group-Clinical Pharmacology of Haemostasis (2008) Methods to evaluate the pharmacology of oral antiplatelet drugs. Herz 33:287-296
11. Ben-Dor I, Kleiman NS, Lev E (2009) Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol 104:227-233
12. Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M, Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R (2009) Interindividual variability in the response to oral antiplatelet drugs: a position paper of the working group on antiplatelet drugs resistance appointed by the section of cardiovascular interventions of the Polish cardiac society, endorsed by the working group on thrombosis of the European society of cardiology. Eur Heart J 30:426-435
13. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339
14. Ivandic BT, Giannitsis E, Schlick P, Staritz P, Katus HA, Hohlfeld T (2007) Determination of aspirin responsiveness by use of whole blood platelet aggregometry. Clin Chem 53:614-619
15. Neubauer H, Kaiser AF, Endres HG, Krüger JC, Engelhardt A, Lask S, Pepinghege F, Kusber A, Mügge A (2011) Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance-the Bochum Clopidogrel and Aspirin plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med 9:3
16. Meves SH, Overbeck U, Endres HG, Krogias C, Neubauer H (2012) Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke. Thromb Haemost 107:69-79
17. Vickrey BG, Rector TS, Wickstrom SL, Guzy PM, Sloss EM, Gorelick PB, Garber S, McCaffrey DF, Dake MD, Levin RA (2002) Occurrence of secondary ischemic events among persons with atherosclerotic vascular disease. Stroke 33:901-906
18. Achterberg S, Cramer MJ, Kappelle LJ, De Borst GJ, Visseren FL, van der Graaf Y, Algra A, SMART study Group (2010) Patients with coronary, cerebrovascular or peripheral arterial obstructive disease differ in risk for new vascular events and mortality: the SMART study. Eur J Cardiovasc Prev Rehabil 17:424-430
19. Cacoub PP, Zeymer U, Limbourg T, Baumgartner I, Poldermans D, Röther J, Bhatt DL, Steg PG, REACH Registry Investigator (2011) Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the Reduction of Atherothrombosis for Continued Health (REACH) registry Europe. Heart 97:660-667
20. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Röther J, Wilson PW, REACH Registry Investigators (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180-189
21. Bongard V, Cambou JP, Lezorovcz A, Ferrères J, Vahanan A, Jullen G, Coppe G, Guerllot M, Herrmann MA, Mas JL (2004) Comparison of cardiovascular risk factors and drug use in 14,544 French patients with a history of myocardial infarction, ischaemic stroke and/or peripheral arterial disease. Eur J Cardiovasc Prev Rehabil 11:394-402
22. Grotemeyer KH, Scharafinski HW, Husstedt IW (1993) Two-year follow-up of aspirin responder and aspirin non responder: a pilot-study including 180 post-stroke patients. Thromb Res 71:397-403
23. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H (2003) Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 250:63-66
24. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003) A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41:961-965
25. Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, Koppensteiner R, Ergun E, Mittlboeck M, Schreiner W, Losert U, Wolner E (1997) Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78:1003-1007
26. Gengo FM, Rainka M, Robson M, Gengo MF, Forrest A, Hourihane M, Bates V (2008) Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol 48:335-343
27. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, Orion D, Israeli-Korn S, Chapman J, Savion N, Varon D, Tanne D (2008) Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 25:355-361
28. Zheng AS, Churilov L, Colley RE, Goh C, Davis SM, Yan B (2013) Association of aspirin resistance with increased stroke severity and infarct size. JAMA Neurol 70:208-213
29. Franks ZG, Campbell RA, Weyrich AS, Rondina MT (2010) Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke. Ann N Y Acad Sci 1207:11-17
30. Garlichs CD, Kozina S, Fateh-Moghadam S, Handschu R, Tomandl B, Stumpf C, Eskafi S, Raaz D, Schmeisser A, Yilmaz A, Ludwig J, Neundörfer B, Daniel WG (2003) Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 34:1412-1418
31. Grove EL (2012) Antiplatelet effect of aspirin in patients with coronary artery disease. Dan Med J 59:B4506
32. McCabe DJ, Harrison P, Mackie IJ, Sidhu PS, Purdy G, Lawrie AS, Watt H, Brown MM, Machin SJ (2004) Platelet degranulation and monocyte-platelet complex formation are increased in the acute and convalescent phases after ischaemic stroke or transient ischaemic attack. Br J Haematol 125:777-787
33. Bauer SM, Cayne NS, Veith FJ (2010) New developments in the preoperative evaluation and perioperative management of coronary artery disease in patients undergoing vascular surgery. J Vasc Surg 51:242-251
34. Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B, Savion N, Varon D, Matetzky S (2011) Relation of aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute myocardial infarction. Am J Cardiol 107:339-342
35. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2010) High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost 104:279-286
36. Zimmermann N, Wenk A, Kim U, Kienzle P, Weber AA, Gams E, Schrör K, Hohlfeld T (2003) Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 108:542-547
37. Blais N, Pharand C, Lordkipanidzé M, Sia YK, Merhi Y, Diodati JG (2009) Response to aspirin in healthy individuals: cross-comparison of light transmission aggregometry, verifynow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2). Thromb Haemost 102:404-411
38. Meves SH, Neubauer H, Overbeck U, Endres HG (2011) Is there an ideal way to initiate antiplatelet therapy with aspirin? a crossover study on healthy volunteers evaluating different dosing schemes with whole blood aggregometry. BMC Res Notes 4:106
39. Rajagopalan S, Mckay I, Ford I, Bachoo P, Greaves M, Brittenden J (2007) Platelet activation increases with the severity of peripheral arterial disease: implications for clinical management. J Vasc Surg 46:485-490
40. Lee WJ, Sheu WH, Chen YT, Liu TJ, Liang KW, Ting CT, Lee WL (2006) Circulating CD40 ligand is elevated only in patients with more advanced symptomatic peripheral arterial diseases. Thromb Res 118:619-626
41. Nambi V, Kimball KT, Bray PF, Bergeron AL, Johnson SL, Morrisett JD, Chen C, Lin PH, Lumsden AB, Ballantyne CM, Dong JF (2009) Differences in responses of platelets to fluid shear stress in patients with peripheral artery disease (PAD) and coronary artery disease (CAD). Platelets 20:199-205
42. Hobson AR, Qureshi Z, Banks P, Curzen NP (2009) Effects of clopidogrel on "aspirin specific" pathways of platelet inhibition. Platelets 20:386-390
43. Armstrong PC, Dhanji AR, Tucker AT, Mitchell JA, Warner TD (2010) Reduction of platelet thromboxane A2 production ex vivo and in vivo by clopidogrel therapy. J Thromb Haemost 8:613-615
44. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC (2008) Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 6:46
45. DiChiara J, Bliden KP, Tantry US, Hamed MS, Antonino MJ, Suarez TA, Bailon O, Singla A, Gurbel PA (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes 56:3014-3019
46. Grove EL, Gregersen S (2012) Antiplatelet therapy in patients with diabetes mellitus. Curr Vasc Pharmacol 10:494-505
47. Schnell O, Erbach M, Hummel M (2012) Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diab Vasc Dis Res 9:245-255
48. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davì G, Patrono C (2012) The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 10:1220-1230
49. Giraud MN, Sanduja SK, Felder TB, Illich PA, Dial EJ, Lichtenberger LM (1997) Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther 11:899-906
50. Würtz M, Grove EL, Kristensen SD, Hvas AM (2010) The antiplatelet effect of aspirin is reduced by proton-pump inhibitors in patients with coronary artery disease. Heart 96:368-371
51. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, Anastasopoulou I, Anastasakou E, Kotsi P, Karafoulidou A, Stergiou GS (2009) Do proton-pump inhibitors attenuate the effect of aspirin on platelet aggregation? a randomized crossover study. J Cardiovasc Pharmacol 54:163-168
52. Kasprzak M, Koziński M, Bielis L, Boinska J, Plazuk W, Marciniak A, Budzyński J, Siller-Matula J, Ro D, Kubica J (2009) Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. Cardiol J 16:535-544
53. Würtz M, Hvas AM, Kristensen SD, Grove EL (2012) Platelet aggregation is dependent on platelet count in patients with coronary artery disease. Thromb Res 129:56-61
54. Munger MA, Van Tassell BW, LaFleur J (2007) Medication nonadherence: an unrecognized cardiovascular risk factor. MedGenMed 9:58
55. Lordkipanidzé M (2011) Why an aspirin a day no longer keeps the doctor away. Thromb Haemost 105:209-210